New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
11:09 EDTYOKU, CBS, VJET, CTRX, HZNPOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
News For HZNP;VJET;YOKU;CTRX;CBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
07:26 EDTHZNPWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
April 30, 2015
06:09 EDTCTRXCatamaran reports Q1 adjusted EPS 59c, consensus 57c
Subscribe for More Information
April 29, 2015
17:50 EDTHZNPHorizon Pharma announces HSR waiting period expiration for Hyperion acquisition
Subscribe for More Information
15:00 EDTCTRXNotable companies reporting before tomorrow's open
Subscribe for More Information
08:36 EDTYOKUYouku Tudou and DJI partner for online aerial videography platform
Youku Tudou and DJI formed a partnership to leverage Youku Tudou's online video platform and DJI's line of aerial videography products by building China's first online platform centered on aerial video content, e-tailing, and the aerial video community. Youku Tudou will become the release platform for the quality aerial videos created by DJI products in Mainland China. Youku Tudou will also offer the whole line of DJI products for purchase through Youku Tudou's e-tailing platform.
April 28, 2015
14:09 EDTCBSEarnings Watch: TV network owners to report amid takeover rumors
Subscribe for More Information
April 27, 2015
18:02 EDTCBSFCC Chairman in favor of giving Pandora waiver to buy KXMZ-FM, Bloomberg says
Subscribe for More Information
07:13 EDTCTRXUBM Tech to hold a conference
Subscribe for More Information
07:02 EDTHZNPHorizon announces issuance of additional notice of allowance for Pennsaid 2%
Horizon Pharma announced it received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/497,096, entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID 2% w/w. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the ninth U.S. patent to be listed in the Orange Book for PENNSAID 2%.
06:19 EDTHZNPPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
12:08 EDTCTRXLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Larsen, along with Mary Ptacek, VP of Pharmaceutical Strategies Group and Ruth Krystopolski, EVP of Sanford Health, discuss the 2016-2017 Pharmacy Benefit Managers selling season and which PBMs are poised to gain share, the impact of WBAs growth plans, recent M&A activity and biosimilars on an Analyst/Industry conference call to be held on April 24 at 2 pm.
10:13 EDTHZNPHigh option volume stocks
Subscribe for More Information
April 22, 2015
13:39 EDTVJETAnalyst warns competition growing in 3D printing space
Subscribe for More Information
10:02 EDTCTRXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:26 EDTVJETvoxeljet management to meet with Brean Capital
Subscribe for More Information
09:20 EDTCTRXCatamaran downgraded to Hold from Buy at Maxim
Maxim downgraded Catamaran to Hold citing the takeover by OptumRx as it does not believe another suitor will emerge with a counter bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use